Evidence of association of interleukin-23 receptor gene polymorphisms with Egyptian rheumatoid arthritis patients

Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review

“…Over the years, it became clear that different variants of the IL-23R also played roles in a number of autoimmune diseases like rheumatoid arthritis (Hamdy et al 2015), psoriasis, ankylosing spondylitis, multiple sclerosis, psoriatic arthritis, psoriasis vulgaris, autoimmune thyroid disease, and Graves' ophthalmopathy. This suggested to some that perturbations in the IL-23 signaling pathway were likely relevant to the pathophysiology of these inflammation-based diseases (Safrany & Melegh 2009).…”

“…A major aim of the research by Hamdy et al (2015) was to investigate the association between three SNP in the IL23R gene (rs11209026, rs2201841, rs10889677) and RA in Egyptian patients. The results showed the AA genotype of the rs11209026 (Arg381Gln) SNP was significantly associated with an increased susceptibility to RA (p ¼ 0.001).…”

The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling

“…In PsA, treatment with anti‐IL‐23 antibodies have shown beneficial effects but not in RA so far. Another finding supporting this hypothesis, is the notion that polymorphisms in the IL‐23 receptor (IL‐23R) have been linked to susceptibility for psoriasis and PsA , but are still a matter of debate in RA (Table ) .…”

Insights into IL-23 biology: From structure to function

“…Several studies revealed the association of IL23R and IL12B with psoriasis [94][95][96][97][98]. SNPs of the IL23R gene are also associated with rheumatoid arthritis (RA) [99,100], Behcet' disease [101], ankylosing spondylitis (AS) [102,103], Alzheimer's disease [104], coronary artery disease [105] and allergic rhinitis [106]. IL-23 signaling did not only play an important role in inflammatory processes; the cytokine is also involved in cancer development and A c c e p t e d M a n u s c r i p t progression [107][108][109].…”